Affordable Access

deepdyve-link
Publisher Website

Protective effect of statin therapy on connective tissue growth factor induction by diabetes in vivo and high glucose in vitro.

Authors
  • Yang, Bingmei
  • Hodgkinson, Andrea D
  • Shaw, Nicholas A
  • Millward, Beverley A
  • Demaine, Andrew G
Type
Published Article
Journal
Growth factors (Chur, Switzerland)
Publication Date
Dec 01, 2013
Volume
31
Issue
6
Pages
199–208
Identifiers
DOI: 10.3109/08977194.2013.852189
PMID: 24192280
Source
Medline
License
Unknown

Abstract

Transcriptional activity of connective tissue growth factor (CTGF) promoter in transfected HEK293 cells was determined by luciferase assays. Secreted CTGF in cultured human mesangial cells was measured by enzyme-linked immunosorbent assay (ELISA). CTGF in urine and plasma was also measured in 405 subjects with/without type 2 diabetes. Our results showed that high glucose significantly increased transcription of the promoter in the transfected cells by more than 2.5-folds (p < 0.0005). CTGF secretion was induced by high glucose in the cells (p < 0.0005). These increases were inhibited by simvastatin. Urine CTGF was positively associated with plasma CTGF in both type 2 diabetes (p = 0.0005) and controls (p = 0.01). Urine CTGF levels in patients with macroalbuminuria were significantly higher than patients without macroalbuminuria (p < 0.05). In conclusion, our in vitro study suggests that statin may have a renal-protective effect through the inhibition of CTGF expression. Urine CTGF may be a good marker for the prediction of diabetic nephropathy.

Report this publication

Statistics

Seen <100 times